Last reviewed · How we verify

Hyaluronic acid and silver sulfadiazine — Competitive Intelligence Brief

Hyaluronic acid and silver sulfadiazine (Hyaluronic acid and silver sulfadiazine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical wound care agent / antimicrobial dressing. Area: Dermatology / Wound Care.

marketed Topical wound care agent / antimicrobial dressing Dermatology / Wound Care Small molecule Live · refreshed every 30 min

Target snapshot

Hyaluronic acid and silver sulfadiazine (Hyaluronic acid and silver sulfadiazine) — University of Cagliari. Hyaluronic acid provides a moist wound healing environment while silver sulfadiazine delivers broad-spectrum antimicrobial activity to prevent infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hyaluronic acid and silver sulfadiazine TARGET Hyaluronic acid and silver sulfadiazine University of Cagliari marketed Topical wound care agent / antimicrobial dressing

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical wound care agent / antimicrobial dressing class)

  1. University of Cagliari · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyaluronic acid and silver sulfadiazine — Competitive Intelligence Brief. https://druglandscape.com/ci/hyaluronic-acid-and-silver-sulfadiazine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: